Medtronic is a global leader in implantable medical devices. The company has been flourishing under newly appointed management, which is improving efficiency and the product pipeline. In its fiscal first quarter, the company grew its revenue by 18.5% year over year, which was a quicker pace than the 17.7% rate reported in the previous quarter, despite the declining condition of the global economy. At the same time, gross margin improved to 76.9% from 74.7%. Demand is not likely to fall significantly given its position as a medical company that generally provides products that greatly benefit patients' well-being. A study released yesterday demonstrated that drug-eluting coronary stents perform materially better than normal ones; this is a major product category for Medtronic. It is also making successful inroads towards improving its position in other product categories such as chronic pain relief and glucose monitoring for diabetes patients. The stock's current price reflects excess devaluation along with the broad market, giving it ample room to appreciate. I'm looking for a move to $45 and then $50 longer term.
Imagine seeing a small, private list of stocks with earnings that are growing like wildfire. And yet, their shares have somehow remained underpriced and undervalued. That's the strategy behind Growth Trader. Developed by Zacks' world-class stock screening expert, our tests against historical data show an average gain of +57.2% per year!Learn More>>
Zacks Top Ten Stocks for 2010 are now available! Last year's buy-and-hold picks generated a +29.6% return! This is one of our least expensive and easiest products to use, and also one of the most profitable! Be one of the first to get this year's picks. Learn more about Zacks Top Ten >>
Find Winning Stocks Quickly with Research Wizard, a powerful desktop software program. Start with easy-to-use pre-loaded strategies, then develop your own. Backtest against years of historical data to see how your approach works in any market. Start a Free Trial Today >>
Rated #1 best-performing stock newsletter over the past 10 years by independent Hulbert Financial Digest. Zacks Elite gives you full access to the power of the Zacks Rank, plus the private, hand picked Focus List, Timely Buys and Growth & Income Portfolios. Start a Free Trial Today >>
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Potentially a $60 stock
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment